A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

NCT07680829 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

378

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: DR10624 Subcutaneous Injection
DRUG: Icosapent Ethyl Oral Capsule
DRUG: Matching Placebo Subcutaneous Injection

Sponsor

Zhejiang Doer Biologics Co., Ltd.